Published By
Created On
15 Sep 2022 17:19:52 UTC
Transaction ID
Cost
Safe for Work
Free
Yes
Bombay High Court to Hear COVID-19 Vaccine Death Case
Join The Conversation! | https://trialsitenews.com/
A petitioner in India’s Bombay High Court claims that the COVID-19 vaccine called Covishield killed his daughter and is now seeking compensation for the loss. The claimant argues that his daughter’s death is directly linked to the side effects of Covishield, the viral vector COVID-19 vaccine originally developed by University of Oxford, licensed by AstraZeneca for the Indian subcontinent and other parts of the world, then licensed for production and commercialization to the Serum Institute of India (SII), the world’s busiest vaccine producer. Originally labeled ChAdOx1 nCoV-19, or the Oxford/AstraZeneca vaccine, the U.S. Food and Drug Administration cancelled clinical trials in the U.S. earlier during the pandemic due to safety incidents. India’s drug regulator (Drug Controller General of India) granted emergency authorization for the product at the start of 2021 by SII. TrialSite reported that SII made moves last year lobby the government to remove all liability for these COVID-19 vaccines, much like is the case in the United States with the PREP Act. The claimant has served multiple parties from SII to the Bill Gates Foundation.
...
https://www.youtube.com/watch?v=tLkHxsxKdPs
A petitioner in India’s Bombay High Court claims that the COVID-19 vaccine called Covishield killed his daughter and is now seeking compensation for the loss. The claimant argues that his daughter’s death is directly linked to the side effects of Covishield, the viral vector COVID-19 vaccine originally developed by University of Oxford, licensed by AstraZeneca for the Indian subcontinent and other parts of the world, then licensed for production and commercialization to the Serum Institute of India (SII), the world’s busiest vaccine producer. Originally labeled ChAdOx1 nCoV-19, or the Oxford/AstraZeneca vaccine, the U.S. Food and Drug Administration cancelled clinical trials in the U.S. earlier during the pandemic due to safety incidents. India’s drug regulator (Drug Controller General of India) granted emergency authorization for the product at the start of 2021 by SII. TrialSite reported that SII made moves last year lobby the government to remove all liability for these COVID-19 vaccines, much like is the case in the United States with the PREP Act. The claimant has served multiple parties from SII to the Bill Gates Foundation.
...
https://www.youtube.com/watch?v=tLkHxsxKdPs
Author
Content Type
Unspecified
video/mp4
Language
English
More from the publisher
Controlling
VIDEO
EU CE
eu-censorship-czar-demands-elon-musk
Elon Musk and Donald Trump find themselves under fire from the European Union, which is demanding compliance with its controversial censorship laws. As EU Commissioner Thierry Breton pushes for American platforms to adhere to anti-speech regulations, we witness a shocking intrusion into free speech rights in the US. Join Adrian from The To Be Frank Show as he breaks down the implications of this censorship push, critiques the EU's attempts to control online conversation, and celebrates Musk's fight for free speech against an alliance of leftist bureaucrats. Will the radical left succeed in silencing dissent? Tune in to find out! #FreeSpeech #ElonMusk #Censorship
...
https://www.youtube.com/watch?v=F-o5hys9L_Y
Transaction
Created
1 month ago
Content Type
Language
video/mp4
English
VIDEO
BRITO
britons’-covid-19-vaccine-injured
The COVID-19 vaccine injury program in the United Kingdom (UK) continues to get bad coverage from the middle tier mainstream media. If you Ask most COVID-19 vaccine injury advocates in the UK how they feel about the 44-year-old Vaccine Damage Payment Scheme (VDPS) it is unfit for purpose, and want it reformed.
------------------------------------
Join The Conversation! | https://trialsitenews.com/
...
https://www.youtube.com/watch?v=w2npN9J_ing
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
CLINI
clinical-trials-and-research-news-35
EpicentRx Receives FDA Clearance of IND for Adenovirus Program AIM-001.
Gates Foundation Places $100m into Battling #COVID19 Including University of Leuven Virologist.
Toronto’s AI-vendor Cyclica Inks Strategic Collaboration with Elite Chinese Academic Research Center targeting COVID-19.
Nationwide Children’s Hospital Submits Proposal to HHS to use Genetically Engineered NK Cells Targeting COVID-19.
Canada Federal Government Continues to Fund #Coronavirus Vaccine Research.
Genentech’s Esbriet Granted Breakthrough Therapy Designation for Unclassifiable Interstitial Lung Disease.
Karyopharm Announces Xpovio (selinexor) Combo Treatment Meets Primary Endpoint in Phase 3 BOSTON Study for Multiple Myeloma.
City of Hope Launches Phase I CAR T Therapy Trial based on Scorpion Toxin.
UTSW & Univ of Chicago Researchers Study Reveals Gut Bacteria can Penetrate Tumors Aiding Cancer Therapy.
UT Health San Antonio at the Forefront of the Clinical Research as a Care Option Movement for Latino Population in Southwest.
The World’s First NASH Drug Approved in India: Zydus Cadila’s Saroglitazar.
CHU Bichat-Claude Bernard Investigators (France) Study #HidradenitisSuppurativa and Conclude a Food Intolerance & Gut Dysbiosis Link.
University of Alberta Spinoff DrugBank Profiles 13K Drug Entries & Seeks Investment.
$2.5m Infused into Western Australia National Imaging Facility Node for Improved Research & Patient Care.
Piedmont Atlanta Hospital is the Lead Enrolling Site for National Transplant Clinical Trials.
Boston’s Cure Rare Disease on the Cusp of CRISPR-based Personalized Treatment for type of Duchenne Muscular Dystrophy.
AMSSM’s Research Network Funds Research to Prepare for NIH-Funded Trial Centering on Achilles Tendinopathy.
CORONAVIRUS/ VIRUS 00.31
LUNG DISEASE 03.01
CANCER 03.30
LIVER DISEASE 05.21
AUTOIMMUNE 05.43
CLINICAL TRIAL 06.14
...
https://www.youtube.com/watch?v=7aph_csF8mA
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
NEWS
news-roundup-australia-planning-to
Join The Conversation! | https://trialsitenews.com/
Australia’s vaccine injury compensation claims scheme expanded recently to children under four years of age. Greg Hunt, the nation’s Health Minister declared that “Vaccination against Covid-19 remains the most effective way to prevent severe disease, hospitalization and death,” in a joint media release with Aged Care Minister Richard Colbeck, Regional Health Minister David Gillespie and Mental Health Minister David Coleman.
...
https://www.youtube.com/watch?v=_BHaVZswlu8
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
CLINI
clinical-trials-and-research-roundup
‘Generic Drug Repurposing for COVID-19” The Israeli Perspective’:
Tel Aviv University’s Spark program recently hosted a webinar titled “Generic Drug Repurposing for COVID-19: The Israeli Perspective.” In collaboration with the MedInsight Institute, presenters included Professor Alex Jadad, Faculty of Medicine and School of Public Health, University of Toronto, Canada; Moshe Rogosnitzky, Executive Director, MedInsight Research Institute from both New York and Israel; professor Yaakov Nahmias, Director for the Center of Bio engineering, the Hebrew University of Jerusalem; and Professor Eli Schwartz with Sheba Medical Center, Tel Aviv University, #Israel, who presented the “Sheba #Ivermectin Project (SIP).” Establishing a movement in Israel to consider the repurposing of generic drugs for purposes of economically and forcefully targeting #COVID-19, the drugs discussed in this presentation included Ivermectin, are potentially safe, effective and widely accessible. The organizers of this event are clear for the world to hear: “Of the 9,000 currently approved drugs that exist globally, the potential for overcoming COVID-19 certainly exists.”
https://trialsitenews.com/generic-drug-repurposing-for-covid-19-the-israeli-perspective/
The FLCCC Alliance press conference from Houston, Texas:
Some Highlights from the press conference starring the Frontline COVID19 Critical Care Alliance from Houston, Texas to discuss emerging evidence for economical and widely available therapeutic possible options for treating early-stage COVID-19 cases.
See the whole press conference here: https://www.youtube.com/watch?v=4V3yxrJwJQs&feature=youtu.be
Great Plains Health Severe COVID-19 Patients Benefit from RLF-100:
Recently showcased on local media, North Platte Nebraska’s Great Plains Health (GPH) has treated at least 20 patients with Aviptadil (RLF-100), an investigational product recently submitted for emergency use authorization in late September. One of those surviving patients, Mark Cardenas, went on air to share his experience and thanks for the access. It literally may have saved his life. Produced by a Swiss company called Relief Therapeutics, Great Plains Health infectious disease physician Eduardo Freitas heard about the drug via a network of other physicians. It was through that network that Dr. Freitas was able to secure a communication channel with U.S and Israel-based NeuroRx, the biotechnology company that co develops the drug for commercialization. TrialSite has reported on a few situations in Texas where patients with severe COVID-19 experienced marked improvement thanks to access to the drug opened up by the U.S. Food and Drug Administration via clinical trials and Expanded Access Protocol. It is through the latter that GPH was able
...
https://www.youtube.com/watch?v=rrlS1Mt8rQ8
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
THE W
the-watchlist-series-kevzara-failure-are
Welcome to another episode of the Watchlist Series. Today, we take a look at #IL6Inhibitors, and whether or not, they are the right class of biologic to be testing on #COVID19 Patients.
#Regeneron and Sanofi announced that the U.S. Phase 3 clinical trial of #Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation failed to meet its primary and key secondary endpoints when the drug was added to best supportive care compared to best supportive care alone (placebo). In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients included multi-organ dysfunction syndrome (6% Kevzara, 5% placebo) and hypotension (4% Kevzara and 3% placebo). The industry sponsors have halted this U.S.-based clinical trial, including a second cohort of patients who received a higher dose of Kevzara (800 mg), based on these findings. Both Regeneron and Sanofi have commented in a press release to submit detailed peer-reviewed disclosure of what happened in this partially publicly financed clinical trial. There are several other Kevzara studies ongoing involving COVID-19 patients: what are the implications of the results from those studies? What about the 43 Actemra (tocilizumab) clinical trials associated with COVID-19 patients and the failed Italian tocilizumab (Actemra) study? Is their growing evidence that pharma company’s pursuit of repurposing IL-6 inhibitors against COVID-19 is a failed strategy? After all, clinical trials are expensive and, as is the case in this U.S., study public funds can be involved. How can these funds be best utilized to protect patients?
https://www.trialsitenews.com/does-kevzara-failure-in-covid-19-patients-requiring-mechanical-ventilation-implicate-other-repurposed-autoimmune-drugs-in-the-war-on-covid-19/
...
https://www.youtube.com/watch?v=gf_oY1WmYZM
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
HARTM
hartmut-ehrlich-and-philippe-pouletty
Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn's Disease and more.
https://www.abivax.com/pipeline/
- #COVID-19
https://www.abivax.com/pipeline/abx464-for-covid-19/
Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial), the unique properties of the lead candidate (antiviral, anti-inflammatory, tissue repair) to treat elderly and high-risk Covid-19 patients, the rial is ongoing in Europe and Brazil (Mexico, Peru and Chile to follow shortly)
-#Cancer
https://www.abivax.com/pipeline/abx196/
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies agonists of these types of cells that demonstrate immune enhancing effects in cancer models.
Preclinical data showed that ABX196 enhanced anti-tumoral activity when used alone and in combination with anti-PD1 antibodies or doxorubicin.
- Ulcerative Colitis
https://www.abivax.com/pipeline/abx464-ibd-uc/
ABX464 in Inflammatory Bowel Diseases (Abivax development priority), excellent two-year efficacy and safety data for ABX464 ulcerative colitis Phase 2a maintenance study and ongoing ulcerative colitis Phase 2b trial in 15 countries, the US and Canada
- Crohn’s disease
https://www.abivax.com/pipeline/abx464-for-crohns-disease/
Planned pivotal Phase 2b/3 trial with ABX464 in Crohn’s disease (FPI Q1 2021) and ngoing clinical trial with ABX464 in rheumatoid arthritis in 5 European countries
- HC
Ongoing clinical trial with second molecule, ABX196, in patients with hepatocellular carcinoma in the US
...
https://www.youtube.com/watch?v=4FVZfU9TnNs
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
CLINI
clinical-trials-and-research-news-58
An Old Drug Tackles New Tricks: #Ivermectin Treatment in Three Brazilian Towns:
TrialSite News continues to develop a global network of individuals, from all walks of life, participating and sharing their experiences from around the world. They share a common bond: a dedication to health, community well-being and research, from randomized controlled trials to real world observations and case series observations, contributing important observations related to COVID-19. Alan Cannell is one of these individuals. Originally from the UK, but based in the southern part of Brazil for many years, Mr. Cannell, an engineer by training who has participated in major projects around the world, shares his research observations as to the use of Ivermectin in Brazil. As TrialSite recently discussed, some municipal health departments in Brazil have approved Ivermectin-based regimens targeting COVID-19. This is a similar pattern to observations in some other parts of South America. Ivermectin is not specifically approved for the COVID-19 indication at the national level.
https://www.trialsitenews.com/an-old-drug-tackles-new-tricks-ivermectin-treatment-in-three-brazilian-towns/
#Chinese Academy of Sciences Team’s FDA Approved Ceftazidime Represents Potential COVID-19 Treatment:
Researchers from the Chinese Academy of Sciences uncovered an antibiotic approved for the treatment of pneumonia actually binds to the same receptors that SARS-CoV-2 itself attaches to in human cells. Called ceftazidime, the Chinese researchers suggest this drug could inhibit or even prevent #COVID19. Published recently in the preprint server bioRxiv, this work is not peer reviewed and hence cannot be considered authoritative. Nonetheless, the intriguing findings were derived from an intensive screening of over 3,500 FDA-approved drug targets as well as small molecules.
https://www.trialsitenews.com/chinese-academy-of-sciences-teams-fda-approved-ceftazidime-represents-potential-covid-19-treatment/
University of Buffalo Prepares Melatonin Trial Targeting Mild to Moderate COVID-19:
Could the natural sleep aid melatonin serve as a treatment for patients with mild and moderate COVID-19? Apparently, researchers at the University at Buffalo seek to find out, and the university Institutional Review Board granted approval to proceed. The U.S. Food and Drug Administration (FDA) already granted approval of the Investigational New Drug (IND) Application.
https://www.trialsitenews.com/university-of-buffalo-prepares-melatonin-trial-targeting-mild-to-moderate-covid-19/
Russia Health Ministry Allows Use of Favipiravir for Outpatient COVID-19 Use:
Back on June 1, TrialSite reported that Russian regulators approved a version of favipiravir known as Avifavir for hospitalized patients. Now the Russian Hea
...
https://www.youtube.com/watch?v=DDykBWpBFlc
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
CLINI
clinical-trials-and-research-news-50
#Ivermectin Study Reveals Fantastic Results: 100% of 60 Patients Better in an Average of Just Under 6 Days:
Recently, TrialSite News reported on a study sponsored in Bangladesh by Upazila Health & Family Planning Officer’s (UHFPO) Office, and, First Affiliated Hospital Xi’an Jiaotong University. The observational study was conducted from May 2 to June 5, 2020. The principal investigators observed 181 patients who tested positive for #COVID19. The Research team recently shared the results via preprint server and ResearchGate. The study team concluded that concerning the treatment outcome, adverse effect, and safety, the Ivermectin and #Doxycycline combination was superior to the use of #Hydroxychloroquine and Azithromycin therapy in the case of mild to moderate degree of COVID-19 patients. Although both treatment regimens were observed to be effective for this study, the Ivermectin treatment was superior.
https://www.trialsitenews.com/ivermectin-study-reveals-fantastic-results-100-of-60-patients-better-in-an-average-of-just-under-6-days/
President of Dominican Republic’s Largest Private Health Group Discusses the Success of Ivermectin as a Treatment for Early Stage COVID-19:
The Rescue Group (Grupo Rescue) is a leading national private health network in the Caribbean nation of Dominican Republic. The Rescue Group operates three hospitals, including Punta Cana Medical Center, Bournigal Medical Center and Canela Clinic as well as affiliated referral hospitals, urgent care facilities, and an in-home service in addition to 17 emergency hotel medical centers. José Natalio Redondo, the group’s president, is renowned in Latin America for the incredible success of his Ivermectin protocol used at the Rescue Group hospitals. Dr. Redondo took the time to speak with TrialSite News about the success of the Ivermectin treatment: they have treated 1,300 early stage COVID-19 patients and have observed dramatic results.
https://www.trialsitenews.com/president-of-dominican-republics-largest-private-health-group-discusses-the-success-of-ivermectin-as-a-treatment-for-early-stage-covid-19/
Dr. José Natalio Redondo Contact Email: josenatalioredondo@gmail.com
National University Singapore Launches Large COVID-19 Prophylaxis Study Targeting Ivermectin & HCQ:
The National University of Singapore serves the island nation as a tertiary hospital, clinical training center, and research center for medical and dental faculties. With 1,160 beds serving more than 670,000 outpatients and 49,000 inpatients, NUS is ranked first in Singapore & Asia Pacific and 11th in the world, according to the 2019 QA World University Rankings. This prestigious research organization initiated a large randomized Phase III open-label prophylaxis trial among migrant workers at high-risk
...
https://www.youtube.com/watch?v=VfTvViI8IKI
Transaction
Created
4 months ago
Content Type
Language
video/mp4
English